These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 38194422)

  • 21. Effects of Atractylon on Proliferation and Apoptosis of Intestinal Cancer Cells Through PI3K/AKT/mTOR Signaling Pathway.
    Mao J; Wang X; Yu M; Sun C
    Cell Mol Biol (Noisy-le-grand); 2022 May; 68(5):153-160. PubMed ID: 36029491
    [TBL] [Abstract][Full Text] [Related]  

  • 22. PIK3CA and AKT1 mutations have distinct effects on sensitivity to targeted pathway inhibitors in an isogenic luminal breast cancer model system.
    Beaver JA; Gustin JP; Yi KH; Rajpurohit A; Thomas M; Gilbert SF; Rosen DM; Ho Park B; Lauring J
    Clin Cancer Res; 2013 Oct; 19(19):5413-22. PubMed ID: 23888070
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mechanism of miR-122-5p regulating the activation of PI3K-Akt-mTOR signaling pathway on the cell proliferation and apoptosis of osteosarcoma cells through targeting TP53 gene.
    Li KW; Wang SH; Wei X; Hou YZ; Li ZH
    Eur Rev Med Pharmacol Sci; 2020 Dec; 24(24):12655-12666. PubMed ID: 33378012
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Research on protective mechanism of ibuprofen in myocardial ischemia-reperfusion injury in rats through the PI3K/Akt/mTOR signaling pathway.
    Chi Y; Ma Q; Ding XQ; Qin X; Wang C; Zhang J
    Eur Rev Med Pharmacol Sci; 2019 May; 23(10):4465-4473. PubMed ID: 31173323
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Combination of PI3K and MEK inhibitors yields durable remission in PDX models of PIK3CA-mutated metaplastic breast cancers.
    Coussy F; El Botty R; Lavigne M; Gu C; Fuhrmann L; Briaux A; de Koning L; Dahmani A; Montaudon E; Morisset L; Huguet L; Sourd L; Painsec P; Chateau-Joubert S; Larcher T; Vacher S; Melaabi S; Salomon AV; Marangoni E; Bieche I
    J Hematol Oncol; 2020 Feb; 13(1):13. PubMed ID: 32087759
    [TBL] [Abstract][Full Text] [Related]  

  • 26. MicroRNA-29b Inhibits Angiogenesis by Targeting VEGFA through the MAPK/ERK and PI3K/Akt Signaling Pathways in Endometrial Carcinoma.
    Chen HX; Xu XX; Tan BZ; Zhang Z; Zhou XD
    Cell Physiol Biochem; 2017; 41(3):933-946. PubMed ID: 28222438
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mechanism of gypenosides of Gynostemma pentaphyllum inducing apoptosis of renal cell carcinoma by PI3K/AKT/mTOR pathway.
    Liu H; Li X; Duan Y; Xie JB; Piao XL
    J Ethnopharmacol; 2021 May; 271():113907. PubMed ID: 33556477
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A network pharmacology approach and experimental validation to investigate the anticancer mechanism and potential active targets of ethanol extract of Wei-Tong-Xin against colorectal cancer through induction of apoptosis via PI3K/AKT signaling pathway.
    Lin F; Zhang G; Yang X; Wang M; Wang R; Wan M; Wang J; Wu B; Yan T; Jia Y
    J Ethnopharmacol; 2023 Mar; 303():115933. PubMed ID: 36403742
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Combine MEK inhibition with PI3K/mTOR inhibition exert inhibitory tumor growth effect on KRAS and PIK3CA mutation CRC xenografts due to reduced expression of VEGF and matrix metallopeptidase-9.
    E J; Xing J; Gong H; He J; Zhang W
    Tumour Biol; 2015 Feb; 36(2):1091-7. PubMed ID: 25326806
    [TBL] [Abstract][Full Text] [Related]  

  • 30. MicroRNA-199a-3p inhibits angiogenesis by targeting the VEGF/PI3K/AKT signalling pathway in an in vitro model of diabetic retinopathy.
    Wang L; Liu WX; Huang XG
    Exp Mol Pathol; 2020 Oct; 116():104488. PubMed ID: 32622012
    [TBL] [Abstract][Full Text] [Related]  

  • 31. EG-VEGF silencing inhibits cell proliferation and promotes cell apoptosis in pancreatic carcinoma via PI3K/AKT/mTOR signaling pathway.
    Yan X; Hui Y; Hua Y; Huang L; Wang L; Peng F; Tang C; Liu D; Song J; Wang F
    Biomed Pharmacother; 2019 Jan; 109():762-769. PubMed ID: 30551529
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mutations in FGFR3 and PIK3CA, singly or combined with RAS and AKT1, are associated with AKT but not with MAPK pathway activation in urothelial bladder cancer.
    Juanpere N; Agell L; Lorenzo M; de Muga S; López-Vilaró L; Murillo R; Mojal S; Serrano S; Lorente JA; Lloreta J; Hernández S
    Hum Pathol; 2012 Oct; 43(10):1573-82. PubMed ID: 22417847
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A detailed immunohistochemical analysis of the PI3K/AKT/mTOR pathway in lung cancer: correlation with PIK3CA, AKT1, K-RAS or PTEN mutational status and clinicopathological features.
    Trigka EA; Levidou G; Saetta AA; Chatziandreou I; Tomos P; Thalassinos N; Anastasiou N; Spartalis E; Kavantzas N; Patsouris E; Korkolopoulou P
    Oncol Rep; 2013 Aug; 30(2):623-36. PubMed ID: 23728071
    [TBL] [Abstract][Full Text] [Related]  

  • 34. PIK3CA mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitors.
    Janku F; Tsimberidou AM; Garrido-Laguna I; Wang X; Luthra R; Hong DS; Naing A; Falchook GS; Moroney JW; Piha-Paul SA; Wheler JJ; Moulder SL; Fu S; Kurzrock R
    Mol Cancer Ther; 2011 Mar; 10(3):558-65. PubMed ID: 21216929
    [TBL] [Abstract][Full Text] [Related]  

  • 35. PIK3CA mutation correlates with mTOR pathway expression but not clinical and pathological features in Fibfibroipose vascular anomaly (FAVA).
    Hori Y; Hirose K; Ozeki M; Hata K; Motooka D; Tahara S; Matsui T; Kohara M; Higashihara H; Ono Y; Tanaka K; Toyosawa S; Morii E
    Diagn Pathol; 2022 Jan; 17(1):19. PubMed ID: 35094709
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Electroacupuncture promotes gastrointestinal motility by activating autophagy of Cajal interstitial cells via downregulating PI3K/Akt/mTOR signaling pathway in stomach of diabetic gastro-paresis rats].
    Zhang TH; Zhao ST; Li XY; Xiao XJ; Xiao L; Wei X; Peng Y
    Zhen Ci Yan Jiu; 2022 Dec; 47(12):1060-7. PubMed ID: 36571220
    [TBL] [Abstract][Full Text] [Related]  

  • 37. PIK3CA mutations in advanced cancers: characteristics and outcomes.
    Janku F; Wheler JJ; Naing A; Stepanek VM; Falchook GS; Fu S; Garrido-Laguna I; Tsimberidou AM; Piha-Paul SA; Moulder SL; Lee JJ; Luthra R; Hong DS; Kurzrock R
    Oncotarget; 2012 Dec; 3(12):1566-75. PubMed ID: 23248156
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The Gene Expression Status of the PI3K/AKT/mTOR Pathway in Gastric Cancer Tissues and Cell Lines.
    Riquelme I; Tapia O; Espinoza JA; Leal P; Buchegger K; Sandoval A; Bizama C; Araya JC; Peek RM; Roa JC
    Pathol Oncol Res; 2016 Oct; 22(4):797-805. PubMed ID: 27156070
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Target-based therapeutic matching in early-phase clinical trials in patients with advanced colorectal cancer and PIK3CA mutations.
    Ganesan P; Janku F; Naing A; Hong DS; Tsimberidou AM; Falchook GS; Wheler JJ; Piha-Paul SA; Fu S; Stepanek VM; Lee JJ; Luthra R; Overman MJ; Kopetz ES; Wolff RA; Kurzrock R
    Mol Cancer Ther; 2013 Dec; 12(12):2857-63. PubMed ID: 24092809
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Glutamine protects myocardial ischemia-reperfusion injury in rats through the PI3K/Akt signaling pathway.
    Cui ZH; Zhang XJ; Shang HQ; Wang X; Rong D
    Eur Rev Med Pharmacol Sci; 2020 Jan; 24(1):444-451. PubMed ID: 31957859
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.